TE化疗联合黄芪多糖注射液治疗中晚期乳腺癌临床疗效及对患者血清HER2-ECD TAP水平的影响  

The clinical efficacy of TE chemotherapy combined with astragalus polysaccharide injection in the treatment of advanced breast cancer and its effect on serum HER2-ECD and TAP levels

作　　者：仲广生 郝凯峰 张明芳 Zhong Guangsheng;Hao Kaifeng;Zhang Mingfang(Pingmei Shenma Medical Group General Hospital,Pingdingshan 467000,Henan,China)

机构地区：[1]平煤神马医疗集团总医院,河南平顶山467000

出　　处：《临床心身疾病杂志》2021年第2期15-20,共6页Journal of Clinical Psychosomatic Diseases

摘　　要：目的探讨多西紫杉醇+表柔比星新辅助化疗联合黄芪多糖注射液治疗中晚期乳腺癌临床疗效及对患者血清人表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平的影响。方法将60例中晚期乳腺癌患者按随机数字表法分为两组,各30例。对照组给予多西紫杉醇+表柔比星新辅助化疗,观察组在对照组基础上联合黄芪多糖注射液治疗。观察4个疗程。比较治疗前后两组疗效、肿瘤T分期降期率、保乳手术率、Karnofsky功能状态评分、癌症患者生活质量评定量表评分、CD3+、CD4+/CD8+、血清人类表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平、不良反应发生状况,并采用Spearman相关分析探讨血清人表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平与临床疗效的相关性。结果观察组缓解率、T分期降期率、保乳手术率高于对照组(P<0.05或0.01)。治疗后观察组Karnofsky功能状态评分、CD3+、CD4+/CD8+水平显著高于对照组(P<0.01),癌症患者生活质量评定量表评分、血清人类表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平显著低于对照组(P<0.01)。乳腺癌患者血清人类表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平与临床疗效呈显著负相关(P<0.05)。观察组白细胞下降、脱发、血小板下降、恶心呕吐发生率显著低于对照组(P<0.05)。结论多西紫杉醇+表柔比星新辅助化疗联合黄芪多糖注射液治疗中晚期乳腺癌疗效显著,能下调血清人表皮生长因子受体-2胞外段、肿瘤异常糖链糖蛋白水平,改善患者功能状况及生活质量,降低不良反应发生率。Objective To explore the clinical efficacy of docetaxel+epirubicin neoadjuvant chemotherapy combined with astragalus polysaccharide injection in the treatment of advanced breast cancer and its effect on the human epidermal growth factor receptor-2-extracellular domain(HER2-ECD)and tumor abnormal protein(TAP).Methods A total of 60 patients with advanced breast cancer were divided into two groups according to the random number table method,with 30 cases in each group.The control group was given neoadjuvant chemotherapy with docetaxel and epirubicin,and the observation group was treated with astragalus polysaccharide injection on the basis of the control group.Patients were observed for 4 courses.The therapeutic effect,the reduction rate of T stage,breast conserving surgery rate,Karnofsky performance scale score,QLQ-C30,CD3+,CD4+/CD8+,HER2-ECD,tumor abnormal protein(TAP)levels,and the occurrence of adverse reactions were compared between the two groups.Spearman was used to analyze the correlation between serum HER2-ECD,TAP and curative effect.Results The remission rate,the reduction rate of T stage and breast-conserving surgery rate in the observation group were higher than those in the control group(P<0.05 or 0.01).After treatment,the KPS score,CD3+,CD4+/CD8+levels in the observation group were significantly higher than those in the control group(P<0.01).The QLQ-C30 score,serum HER2-ECD and TAP levels were significantly lower than those of the control group(P<0.01).The levels of HER2-ECD and TAP in breast cancer patients were significantly negatively correlated with clinical efficacy(P<0.05).The incidence of white blood cell decline,hair loss,platelet decline,nausea and vomiting in the observation group were significantly lower than those in the control group(P<0.05).Conclusions Docetaxel+epirubicin neoadjuvant chemotherapy combined with astragalus polysaccharide injection has a significant effect on the treatment of advanced breast cancer,down-regulating the levels of HER2-ECD and TAP,improving the functional stat

关 键 词：乳腺癌 黄芪多糖注射液 化疗 临床疗效 人皮生长因子受体-2胞外段 肿瘤异常糖链糖蛋白 

分 类 号：R737.9[医药卫生—肿瘤]